Randomized phase III study comparing an early PET driven treatment deescalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.

被引：7
|
作者：
Casasnovas, Olivier
Brice, Pauline
Bouabdallah, Reda
Salles, Gilles A.
Stamatoulas, Aspasia
Dupuis, Jehan
Reman, Oumedaly
Gastinne, Thomas
Joly, Bertrand
Bouabdallah, Kamal
Nicolas-Virelizier, Emmanuelle
Feugier, Pierre
Morschhauser, Franck
Delarue, Richard
Berriolo-Riedinger, Alina
Edeline, Veronique
Traverse-Glehen, Alexandra
Andre, Marc
Mounier, Nicolas
Meignan, Michel
机构：
[1] CHU Bocage, Serv Hematol Clin, Dijon, France
[2] Paris Diderot Sorbonne Univ, St Louis Hosp, AP HP, Paris, France
[3] Inst Paoli Calmettes, Marseille, France
[4] Ctr Hosp, Serv Hematol, Lyon, France
[5] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[6] CHU Henri Mondor, Dept Hematol, Creteil, France
[7] Ctr Hosp Univ Caen, Dept Hematol, Caen, France
[8] CHU Nantes, Dept Hematol, Nantes, France
[9] Ctr Hosp Sud Francilien, Corbeil Essonnes, France
[10] Univ Hosp Bordeaux, Dept Haematol, Bordeaux, France
[11] Ctr Leon Berard, Dept Hematol, Lyon, France
[12] CHU Nancy, Dept Hematol, Nancy, France
[13] Ctr Hosp Reg Univ CHRU Lille, Dept Clin Hematol, Lille, France
[14] Univ Lille 2, Unite Grp Rech Formes Injetables & Technol Associ, Lille, France
[15] Hop Necker Enfants Malad, Dept Hematol, Paris, France
[16] Ctr Georges Francois Leclerc, Dept Nucl Med, Dijon, France
[17] Inst Curie, Paris, France
[18] Hosp Civils Lyon Hop Lyon Sud, Pierre Benite, France
[19] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium
[20] CHU Archet, Dept Hematol, Nice, France
[21] Hop Henri Mondor, LYSA IM, Creteil, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase III Study Comparing an Early PET Driven Treatment De Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
    Casasnovas, Olivier
    Brice, Pauline
    Bouabdallah, Reda
    Salles, Gilles A.
    Stamatoullas, Aspasia
    Dupuis, Jehan
    Reman, Oumedaly
    Gastinne, Thomas
    Joly, Bertrand
    Bouabdallah, Krimo
    Nicolas-Virelizier, Emmanuelle
    Bologna, Serge
    Morschhauser, Franck
    Delarue, Richard
    Farhat, Hassan
    Quittet, Philippe
    Berriolo-Riedinger, Alina
    Tempescul, Adrian
    Edeline, Veronique
    Maisonneuve, Herve
    Eisenmann, Jean Claude
    Traverse-Glehen, Alexandra
    Andre, Marc
    Mounier, Nicolas
    Meignan, Michel
    Ferme, Christophe
    BLOOD, 2015, 126 (23)
  • [2] Randomized Phase III Study Comparing an Early PET-Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients With Advanced-Stages Hodgkin Lymphoma: Final Analysis of the AHL2011 LYSA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 9 - 11
  • [3] Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
    Demeestere, Isabelle
    Racape, Judith
    Dechene, Julie
    Dupuis, Jehan
    Morschhauser, Franck
    De Wilde, Virginie
    Lazarovici, Julien
    Ghesquieres, Herve
    Touati, Mohamed
    Sibon, David
    Alexis, Magda
    Gac, Anne-Claire
    Moatti, Hannah
    Virelizier, Emmanuelle
    Maisonneuve, Herve
    Pranger, Delphine
    Houot, Roch
    Fornecker, Luc-Matthieu
    Tempescul, Adrian
    Andre, Marc
    Casasnovas, Rene-Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (29) : 3251 - +
  • [4] Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study
    Casasnovas, Rene-Olivier
    Bouabdallah, Reda
    Brice, Pauline
    Lazarovici, Julien
    Ghesquieres, Herve
    Stamatoullas, Aspasia
    Dupuis, Jehan
    Gac, Anne-Claire
    Gastinne, Thomas
    Joly, Bertrand
    Bouabdallah, Krimo
    Nicolas-Virelizier, Emmanuelle
    Feugier, Pierre
    Morschhauser, Franck
    Sibon, David
    Bonnet, Christophe
    Berriolo-Riedinger, Alina
    Edeline, Veronique
    Parrens, Marie
    Damotte, Diane
    Coso, Diane
    Andre, Marc
    Meignan, Michel
    Rossi, Cedric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (10) : 1091 - +
  • [5] AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.
    Casasnovas, Rene-Olivier
    Meignan, Michel
    Reman, Oumedaly
    Gaillard, Isabelle
    Stamatoullas, Aspasia
    Brice, Pauline
    Salles, Gilles A.
    Bouabdallah, Reda
    Bologna, Serge
    Nicolas-Virelizier, Emmanuelle
    Morschhauser, Franck
    Janvier, Maud
    Andre, Marc
    Berriolo-Riedinger, Alina
    Traverse-Glehen, Alexandra
    Edeline, Veronique
    Dartigues, Peggy
    Parrens, Marie
    Mounier, Nicolas
    Ferme, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
    Casasnovas, Rene-Olivier
    Bouabdallah, Reda
    Brice, Pauline
    Lazarovici, Julien
    Ghesquieres, Herve
    Stamatoullas, Aspasia
    Dupuis, Jehan
    Gac, Anne-Claire
    Gastinne, Thomas
    Joly, Bertrand
    Bouabdallah, Krimo
    Nicolas-Virelizier, Emmanuelle
    Feugier, Pierre
    Morschhauser, Franck
    Delarue, Richard
    Farhat, Hassan
    Quittet, Philippe
    Berriolo-Riedinger, Alina
    Ternpescul, Adrian
    Edeline, Veronique
    Maisonneuve, Nerve
    Fomecker, Luc-Matthieu
    Lamy, Thiery
    Delmer, Alain
    Dartigues, Peggy
    Martin, Laurent
    Andre, Marc
    Moonier, Nicolas
    Traverse-Glehen, Alexandra
    Meignan, Michel
    LANCET ONCOLOGY, 2019, 20 (02): : 202 - 215
  • [7] PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
    Casasnovas, Olivier
    Racape, Judith
    Dechene, Julie
    Bouabdallah, Reda
    Brice, Pauline
    Lazarovici, Julien
    Ghesquieres, Herve
    Bastard, Aspasia Stamatoulas
    Dupuis, Jehan
    Gac, Anne-Claire
    Gastinne, Thomas
    Joly, Bertrand
    Bouabdallah, Krimo
    Nicolas-Virelizier, Emmanuelle
    Feugier, Pierre
    Morschhauser, Franck
    Andre, Marc
    Berriolo-Riedinger, Alina
    Edeline, Veronique
    Joubert, Clementine
    Meignan, Michel
    Demeestere, Isabelle
    BLOOD, 2020, 136
  • [8] PET-Guided Strategy Improves the Safety of BEACOPP-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the Lysa AHL 2011 Phase 3 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 17 - 19
  • [9] Ovarian function recovery in newly diagnosed advanced Hodgkin lymphoma patients treated with PET-adapted regimen: prospective analysis of a mu Iticentric randomized phase 3 trial (AHL2011)
    Demeestere, I.
    Dechene, J.
    Racape, J.
    Bouabdallah, R.
    Brice, P.
    Ghesquieres, H.
    Stamatoulas, A.
    Dupuisl, J.
    Gac, A. G.
    Gastinne, T.
    Joly', B.
    Bouabdallah, K.
    Casasnovas, O., I
    HUMAN REPRODUCTION, 2020, 35 : 17 - 18
  • [10] The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study
    Traverse-Glehen, Alexandra
    Damotte, Diane
    Dartigues, Peggy
    Martin, Laurent
    Parrens, Marie
    Guesquieres, Herve
    Sarkozy, Clementine
    Deau, Benedicte
    Bouabdallah, Reda
    Garciaz, Sylvain
    Meignan, Michel
    Edeline, Veronique
    Kanoun, Salim
    Berriolo-Riedinger, Alina
    Brice, Pauline
    Rossi, Cedric
    Stamatoullas, Aspasia
    Veillard, Anne Sophie
    Andre, Marc
    Casasnovas, Olivier
    BLOOD, 2016, 128 (22)
12345